|
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
RASSF1A promoter methylation was associated with tumor grade (grade 3-4 vs 1-2: OR 2.31, 95% CI 1.12-4.77, P = 0.023), lymph node metastasis (yes vs no: OR 2.97, 95% CI 1.60-5.52, P = 0.001), tumor histology (squamous cell carcinoma vs adenocarcinoma: OR 0.49, 95% CI 0.22-1.08, P = 0.076), and HPV infection (positive vs negative: OR 0.45, 95% CI 0.28-0.73, P = 0.001).
|
29288321 |
2018 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These percentages and the corresponding ones for EPB41L3, RASSF1 and RASSF2 genes were also higher in SCCs than in ADCs, except for P16.
|
26222671 |
2015 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of all three TSGs were significantly different between NSCLC subtypes: RASSF1A and FUS1 expression levels were significantly lower in squamous cell carcinoma (SCC), and NPRL2/G21 in adenocarcinoma (AC).
|
26112163 |
2015 |
|
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The RASSF1A gene promoter was highly methylated in cancer tissues, and there were significant differences between normal esophagus tissues and esophageal squamous carcinoma (P < 0.05).
|
25886188 |
2015 |
|
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
High down-regulation frequency was shown for RBSP3, ITGA9, VILL, APRG1/C3orf35 and RASSF1 (isoform A) genes (3p21.3 locus) in SCC.
|
23478628 |
2013 |
|
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Conversely, there was a trend toward a higher frequency of RASSF1A methylation in ADC than SCC.
|
21507233 |
2011 |
|
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We studied the epigenetic alterations of RASSF1A, RASSF2A, p16, TSP-1 and MGMT genes in vulvar SCCs, LS associated with SCC, isolated LS and normal vulvar skin.
|
20734389 |
2011 |
|
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
A significant association was found between TT genotype and methylation status of the RASSF1A gene in OSCC patients (p = 0.012).
|
20940365 |
2011 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The two-gene combination (RASSF1A/Twist) showed the best performance in distinguishing HSIL/SCC from LSIL/negative samples.
|
20496080 |
2010 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The methylation frequency in normal, LSIL, HSIL, and SCC was significantly different (p<0.01) for eight genes (DAPK, HIC-1, HIN-1, MGMT, RAR-beta, RASSF1A, SHP-1, and Twist).
|
19836067 |
2010 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We examined the promoter hypermethylation status of p16(INK4A) (p16), glutathione S-transferase pi (GSTP1), O(6)-methylguanine-DNA methyltransferase (MGMT), death-associated protein kinase 1 (DAPK1), RAS-association domain family 1, isoform A (RASSF1A), and E-cadherin (CDH1) genes in OSCC tumors.
|
20729138 |
2010 |
|
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma.
|
19509163 |
2009 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Folate concentrations and methylation of LINE-1, RASSF1, and RUNX3 were significantly higher in adenocarcinoma compared to squamous cell carcinoma (SCC).
|
19764999 |
2009 |
|
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
45% of adenocarcinoma tumors showed RASSF1A promoter methylation in comparison to 17% of squamous cell carcinomas and 22% of large cell carcinomas.
|
19926549 |
2009 |
|
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
LHGDN |
Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
|
19148529 |
2009 |
|
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A set of 4 genes, including CDH1 (E-cadherin), SFN (stratifin), RARB (retinoic acid receptor, beta) and RASSF1A (Ras association (RalGDS/AF-6) domain family 1), had their methylation patterns evaluated by MSP (Methylation-Specific Polymerase Chain Reaction) analysis in 49 fresh urinary bladder carcinoma tissues (including 14 cases paired with adjacent normal bladder epithelium, 3 squamous cell carcinomas and 2 adenocarcinomas) and 24 cell sediment samples from bladder washings of patients classified as cancer-free by cytological analysis (control group).
|
18702824 |
2008 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the hypermethylation of RASSF1A or RUNX3 gene is therefore a useful biomarker to predict the prognosis in NSCLC, particularly RASSF1A due to SCCs and RUNX3 due to ACs.
|
17606310 |
2007 |
|
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The frequency of KRAS mutation and RASSF1A methylation were significantly different between adenocarcinomas (P<0.001) and squamous cell carcinomas (P<0.001).
|
17360030 |
2007 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The methylation of RASSF1A was inversely related to HPV infection in patients with HSIL/SCC (P=0.003).
|
17097722 |
2007 |
|
Squamous cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The frequency of cancer-related gene methylation in SCCs was: CDH1 (95%), p16 (20%), p14 (15%), DAPK1 (15%), MGMT (15%), RB1 (5%), RASSF1 (5%), p15 (0%), PTEN (0%), PRDM2 (0%) and p53 (0%).
|
17034532 |
2006 |
|
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, inactivation of RASSF1A and p16 correlated well with an extended smoking habit (P=0.02), and exposure to asbestos (P=0.017) or squamous cell carcinoma (P=0.011), respectively.
|
15911247 |
2005 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
LOH at 3p21.3-3p22.1 (where RASSF1A is located) was detected in only 12% of SCC and 0% of VC.
|
15689228 |
2005 |
|
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
RASSF1A methylation was more frequently observed in adenocarcinomas (28 of 72, 39%) than in squamous cell carcinomas (6 of 45, 13%, P = 0.0033).
|
15541815 |
2004 |
|
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
RASSF1A promoter region CpG island methylation was detected in adenocarcinomas (55%), large cell carcinomas (25%), and squamous cell carcinomas (25%).
|
14511407 |
2004 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although in adenocarcinomas, methylation of RASSF1A and presence of human papillomavirus (HPV) type 16 or 18 sometimes coexisted, not a single case of HPV-16/18-positive squamous cell carcinomas had RASSF1A methylation.
|
12702579 |
2003 |